Your Messages Inbox
Your Article Summary
See Latest ArticlesBristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application
Bristol Myers-Squibb Company, 09/04/09
Bristol–Myers Squibb Company announced that the U.S. Food and Drug Administration has accepted, for filing and review, the company’s submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor